Intraoperative and Post-Op Intravesical Treatment of Non-Muscle Invasive Bladder Cancer
Featured Speaker: Mark A. Preston, MD
Assistant Professor of Surgery
Harvard Medical School
Brigham & Women's Hospital
The treatment of non-muscle invasive bladder cancer (NMIBC) has been based on intravesical therapy for decades. The mainstay of treatment has been BCG based therapy for decades, however, the paradigm is changing. Recent evidence has shown that intravesical placement of chemotherapy at the time of primary resection has markedly decreased recurrence rates. However, the agent of choice is debatable, and evidence is suggesting a new line of treatment maybe in order. It is the hope of this program to elucidate the issues and to enhance the audience's knowledge of the current controversies and allow for a more informed decision making on the part of both physician and patient.
The literature is suggesting that intravesical gemcitabene may be a better agent to use at the time of resection for NMIBC. This is a shift from mitomycin based treatment. This program will help to identify the issues and best practices at this time.
Massachusetts Association of Practicing Urologists
P.O. Box 54-9132
Waltham, MA 02454-9132Ph: email@example.com